Ractigen Therapeutics completed RMB 100mln in Series A financing, led by GL Ventures
Ractigen Therapeutics announced today that it has completed 110 million yuan in Series A financing.
This round of financing was led by GL Ventures, with participation from CCBI Healthcare Growth Fund, Chongqing Boyi Equity Investment Fund Management, and Longmen Capital.
The funds raised will be mainly used for R&D, team expansion, and investigational new drug (IND) application for multiple new drugs in the preclinical stage.
RNA activation (RNAa) is a biological mechanism discovered and named for the first time in the world in 2006 by Dr. Long-Cheng Li, the founder of Ractigen Therapeutics. Small activating RNA drugs are a new gene therapy method that treats various diseases caused by protein deletion or low expression, including common diseases caused by single-gene genetic diseases and non-gene mutations.
Ractigen Therapeutics was founded in 2017 in Nantong, Jiangsu by Dr. Longcheng Li and his former laboratory team members Dr. Robert Place and Dr. Moorim Kang, focusing on the development and commercialization of RNA activation technology for the global market.
Since its establishment, the company has focused on single-gene genetic diseases and completed the construction of a new generation of unique saRNA platform technology and innovative small nucleic acid delivery platform technology.
At present, the company has established a world-leading RNA-activated drug discovery and development platform and a R&D pipeline containing more than 10 new drug projects.
The company owns all of their independent intellectual property rights, covering single-gene genetic diseases, tumor diseases, liver metabolism, blood system diseases, skin diseases and other fields.